Get started
Relmada Therapeutics IncRelmada Therapeutics IncRelmada Therapeutics Inc

Relmada Therapeutics Inc

No trades
See on Supercharts
OverviewFinancialsNewsIdeasDiscussionsTechnicalsForecastSeasonalsETFs

4E2 chart


Full chart

4E2 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪58.98 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.88 EUR
Net income (FY)
‪−77.26 M‬ EUR
Revenue (FY)
0.00 EUR
Shares float
‪26.44 M‬
Beta (1Y)
1.62

Employees


Employees (FY)
17
Change (1Y)
−3 −15.00%
Revenue / Employee (1Y)
0.00 EUR
Net income / Employee (1Y)
‪−4.54 M‬ EUR

About Relmada Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Sergio Traversa
Website
relmada.com
Headquarters
Coral Gables
Founded
2012
ISIN
US75955J4022
FIGI
BBG01B8WHBX6
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Check out other big names from the same industry as 4E2.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

4E2 news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs with 4E2 exposure


PSIL
AdvisorShares Psychedelics ETF
Weight
4.63%
Market value
‪885.64 K‬
USD
DX2D
Xtrackers LPX MM PRIVATE EQUITY UCITS ETF Capitalisation 1C
Weight
0.10%
Market value
‪467.28 K‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of 4E2 is 1.70 EUR — it has decreased by −2.31% in the past 24 hours. Watch Relmada Therapeutics Inc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange Relmada Therapeutics Inc stocks are traded under the ticker 4E2.
4E2 stock has risen by 9.03% compared to the previous week, the month change is a 49.56% rise, over the last year Relmada Therapeutics Inc has showed a −44.44% decrease.
We've gathered analysts' opinions on Relmada Therapeutics Inc future price: according to them, 4E2 price has a max estimate of 0.92 EUR and a min estimate of 0.92 EUR. Watch 4E2 chart and read a more detailed Relmada Therapeutics Inc stock forecast: see what analysts think of Relmada Therapeutics Inc and suggest that you do with its stocks.
4E2 reached its all-time high on Nov 4, 2022 with the price of 6.85 EUR, and its all-time low was 0.10 EUR and was reached on Mar 3, 2025. View more price dynamics on 4E2 chart.
See other stocks reaching their highest and lowest prices.
4E2 stock is 5.99% volatile and has beta coefficient of 1.62. Track Relmada Therapeutics Inc stock price on the chart and check out the list of the most volatile stocks — is Relmada Therapeutics Inc there?
Today Relmada Therapeutics Inc has the market capitalization of ‪58.98 M‬, it has increased by 3.73% over the last week.
Yes, you can track Relmada Therapeutics Inc financials in yearly and quarterly reports right on TradingView.
Relmada Therapeutics Inc is going to release the next earnings report on Nov 6, 2025. Keep track of upcoming events with our Earnings Calendar.
4E2 earnings for the last quarter are −0.25 EUR per share, whereas the estimation was −0.39 EUR resulting in a 34.78% surprise. The estimated earnings for the next quarter are −0.38 EUR per share. See more details about Relmada Therapeutics Inc earnings.
Relmada Therapeutics Inc revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
4E2 net income for the last quarter is ‪−8.38 M‬ EUR, while the quarter before that showed ‪−16.23 M‬ EUR of net income which accounts for 48.40% change. Track more Relmada Therapeutics Inc financial stats to get the full picture.
No, 4E2 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 8, 2025, the company has 17 employees. See our rating of the largest employees — is Relmada Therapeutics Inc on this list?
Like other stocks, 4E2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Relmada Therapeutics Inc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Relmada Therapeutics Inc technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Relmada Therapeutics Inc stock shows the buy signal. See more of Relmada Therapeutics Inc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.